Table 1

Table showing demographics, aetiology, precipitant and disease severity scores of decompensated cirrhosis admissions

TotalPre-COVID-19COVID-19P value
Male264 (67.7%)161 (65.2%)117 (70.1%)0.186
Female126 (32.3%)86 (34.8%)50 (29.9%)
Age
 Median (IQR)58 (16)59 (17)57 (15.5)0.314
 <30106 (1.7%)4 (1.7%)
 30–5013671 (20.3%)65 (27%)
 50–70316192 (54.9%)123 (51%)
 >7010059 (16.9%)41 (17%)
Ethnicity
 White247 (63.3%)149 (60.3%)113 (67.7%)0.146
 Asian37 (9.5%)27 (10.9%)11 (6.6%)
 Black17 (4.4%)13 (5.3%)5 (3%)
 Other81 (20.8%)50 (20.2%)38 (22.8%)
 Mixed1 (0.3%)1 (0.4%)0
 Not stated7 (1.8%)7 (2.8%)0
Comorbidities
 Diabetes87 (22.3%)61 (24.7%)32 (19.2%)0.135
 Cardiac48 (12.3%)31 (12.6%)21 (12.6%)0.845
 Respiratory52 (13.3%)33 (13.4%)20 (12%)0.98
 Chronic kidney disease24 (6.2%)16 (6.5%)11 (6.6%)0.724
 Neurological26 (6.7%)18 (7.3%)13 (7.8%)0.516
 Malignancy33 (8.5%)25 (10.1%)9 (5.4%)0.121
 Other81 (20.8%)61 (24.47%)24 (14.4%)0.03
Aetiology
 Alcohol246 (63.1%)152 (61.5%)110 (65.9%)0.401
 Nonalcoholic steatohepatitis (NASH)55 (14.1%)40 (16.2%)23 (13.8%)
 Hepatitis C49 (12.6%)33 (13.4%)18 (10.8%)
 Hepatitis B19 (4.9%)13 (5.3%)6 (3.6%)
 Autoimmune hepatitis25 (6.4%)13 (5.3%)12 (7.2%)
 Primary biliary cirrhosis8 (2.1%)7 (2.8%)1 (0.6%)
 Primary sclerosing cholangitis11 (2.8%)8 (3.2%)3 (1.8%)
 Cryptogenic cirrhosis11 (2.8%)9 (3.6%)3 (1.8%)
 Wilson’s disease3 (0.8%)2 (0.8%)2 (1.2%)
 Other9 (2.3%)5 (2%)4 (2.4%)
Precipitant
 Alcohol150 (25.4%)82 (23.5%)59 (35.3%)0.301
 Infection131 (22.2%)79 (22.6%)31 (18.6%)
 Gastrointestinal haemorrhage111 (18.8%)73 (20.9%)37 (15.4%)
  Varices75 (67.6%)47 (64.4%)28 (75.7%)
 Hepatitis B reactivation2 (0.3%)2 (0.6%)0
 New portal vein thrombosis1 (0.2%)01 (0.6%)
 Hepatocellular carcinoma5 (0.8%)2 (0.6%)3 (1.8%)
 Autoimmune flare3 (0.5%)1 (0.3%)2 (1.2%)
 Drug-induced liver injury2 (0.3%)2 (0.6%)0
 Unknown185 (31.3%)108 (30.9%)47 (28.1%)
Disease severity scores on admission (median, IQR)
 UKELD56 (10)56 (10)57 (10)0.392
 MELD Na21 (10)20 (9)21 (11)0.684
 Child Pugh Score10 (3)9 (3)10 (3)0.82
 AD Score54.3 (12.9)54 (13)55 (13)0.69
  • Data have been shown for the total cohort, as well as a breakdown of the pre-COVID-19 and COVID-19 time periods.

  • AD, acute decompensation; MELD Na, Model for End-Stage Liver Disease-Sodium; UKELD, UK Model for End-Stage Liver Disease.